These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 1621002)

  • 41. Biomodulation of chemotherapy-induced myelosuppression.
    Quesenberry PJ
    Semin Oncol; 1992 Jun; 19(3 Suppl 8):8-13. PubMed ID: 1615339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Haematopoietic growth factors in clinical medicine.
    Henschler R; Brugger W; Kanz L; Mertelsmann R
    Eur J Cancer; 1994; 30A(1):118-9. PubMed ID: 7511397
    [No Abstract]   [Full Text] [Related]  

  • 43. Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
    Pettengell R; Crowther D
    Ann Oncol; 1994; 5 Suppl 2():133-41. PubMed ID: 7911317
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mobilization of peripheral stem cells for transplantation.
    Nemunaitis J; Rosenfeld C
    J Hematother; 1993; 2(3):351-5. PubMed ID: 7921995
    [No Abstract]   [Full Text] [Related]  

  • 45. High dose chemotherapy with haemopoietic support for breast cancer.
    Steward WP
    Eur J Cancer; 1995; 31A Suppl 7():S21-4. PubMed ID: 8562187
    [No Abstract]   [Full Text] [Related]  

  • 46. Dose optimisation and intensification of cytotoxics in solid tumours supported by haematopoietic growth factors.
    Le Chevalier T
    Eur J Cancer; 1994; 30A(3):410-2. PubMed ID: 8204370
    [No Abstract]   [Full Text] [Related]  

  • 47. Chemotherapy and complications in gynecologic cancer.
    ten Bokkel Huinink WW
    Curr Opin Oncol; 1991 Oct; 3(5):930-2. PubMed ID: 1751584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic use of hematopoietic growth factors in bone marrow transplantation.
    Nimer SD; Champlin RE
    Cancer Treat Res; 1990; 50():141-64. PubMed ID: 1976348
    [No Abstract]   [Full Text] [Related]  

  • 49. Rescue of haemopoiesis by a combination of growth factors including stem-cell factor.
    Blaise D; Faucher C; Vey N; Caraux J; Maraninchi D; Chabannon C
    Lancet; 2000 Oct; 356(9238):1325-6. PubMed ID: 11073025
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hemopoietic growth factors: their biological effects and the prospects for their clinical use].
    Dexter TM
    Ontogenez; 1991; 22(4):341-64. PubMed ID: 1945267
    [No Abstract]   [Full Text] [Related]  

  • 51. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hematopoietic growth factors in clinical practice.
    Pitler LR
    Semin Oncol Nurs; 1996 May; 12(2):115-29. PubMed ID: 8727799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The problem of permanent bone marrow damage after cytotoxic drug treatment.
    Lohrmann HP
    Oncology; 1984; 41(3):180-4. PubMed ID: 6374556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mobilization of peripheral blood progenitor cells by hematopoietic growth factors.
    Chao NJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():43-6. PubMed ID: 8853524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hematopoietic growth factors: personalization of risks and benefits.
    Puhalla S; Bhattacharya S; Davidson NE
    Mol Oncol; 2012 Apr; 6(2):237-41. PubMed ID: 22497867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Ayash LJ; Elias A; Wheeler C; Tepler I; Schwartz G; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(4):507-11. PubMed ID: 7916250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical application of hematopoietic growth factors.
    Steward WP; Scarffe JH; Dexter TM; Testa NG
    Immunol Ser; 1990; 49():359-78. PubMed ID: 2090257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
    Mangi MH; Newland AC
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I; Cannistra SA; Frei E; Gonin R; Anderson KC; Demetri G; Niloff J; Goodman H; Muntz H; Muto M
    J Clin Oncol; 1993 Aug; 11(8):1583-91. PubMed ID: 8101563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-1: biological effects in human hematopoiesis.
    Crown J; Jakubowski A; Gabrilove J
    Leuk Lymphoma; 1993 Apr; 9(6):433-40. PubMed ID: 8339049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.